优先审评券与被忽视热带病药物及疫苗研发的关联。
Association of the Priority Review Voucher With Neglected Tropical Disease Drug and Vaccine Development.
作者信息
Jain Nina, Hwang Thomas, Franklin Jessica M, Kesselheim Aaron S
机构信息
Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women's Hospital, Boston, Massachusetts.
出版信息
JAMA. 2017 Jul 25;318(4):388-389. doi: 10.1001/jama.2017.7467.
Abstract
This study uses commercial pharmaceutical database data to evaluate the number of new drugs and vaccines for neglected tropical diseases entering phase 1 clinical trials before and after introduction in 2007 of a priority review voucher program to incentivize development.
摘要
本研究利用商业制药数据库数据，评估在2007年引入优先审评券计划以激励开发前后，进入1期临床试验的被忽视热带病新药和疫苗数量。
相似文献
1
Association of the Priority Review Voucher With Neglected Tropical Disease Drug and Vaccine Development.优先审评券与被忽视热带病药物及疫苗研发的关联。
JAMA. 2017 Jul 25;318(4):388-389. doi: 10.1001/jama.2017.7467.
2
FDA launches priority vouchers for neglected-disease drugs.美国食品药品监督管理局推出针对被忽视疾病药物的优先券。
Nat Biotechnol. 2008 Dec;26(12):1315-6. doi: 10.1038/nbt1208-1315.
3
"Creating hope" and other incentives for drug development for children.为儿童开发药物的“创造希望”和其他激励措施。
Sci Transl Med. 2011 Jan 19;3(66):66cm1. doi: 10.1126/scitranslmed.3001707.
4
Priorities for the Priority Review Voucher.优先审评券的优先事项。
Am J Trop Med Hyg. 2017 Jan 11;96(1):14-15. doi: 10.4269/ajtmh.16-0600. Epub 2016 Aug 29.
5
The Tropical Disease Priority Review Voucher: A Game-Changer for Tropical Disease Products.热带病优先审评券：热带病产品的变革者。
Am J Trop Med Hyg. 2017 Jan 11;96(1):11-13. doi: 10.4269/ajtmh.16-0099. Epub 2016 Aug 29.
6
The Commercial Market For Priority Review Vouchers.优先审评券的商业市场。
Health Aff (Millwood). 2016 May 1;35(5):776-83. doi: 10.1377/hlthaff.2015.1314.
7
Expansion of the Priority Review Voucher Program Under the 21 Century Cures Act: Implications for Innovation and Public Health.《21世纪治愈法案》下优先审评券计划的扩展：对创新和公共卫生的影响
Am J Law Med. 2018 May;44(2-3):329-341. doi: 10.1177/0098858818789430.
8
Preserving an Incentive for Global Health R&D: The Priority Review Voucher Secondary Market.保留全球卫生研发的激励措施：优先审评券二级市场。
Am J Law Med. 2016 May;42(2-3):524-542. doi: 10.1177/0098858816658278.
9
The use of the United States FDA programs as a strategy to advance the development of drug products for neglected tropical diseases.利用美国食品药品监督管理局的项目作为推进被忽视热带病药品研发的一项策略。
Drug Dev Ind Pharm. 2014 Nov;40(11):1429-34. doi: 10.3109/03639045.2014.884132. Epub 2014 Feb 11.
10
Orphan drug legislation: lessons for neglected tropical diseases.罕见病药物立法：被忽视热带病的教训
Int J Health Plann Manage. 2009 Jan-Mar;24(1):27-42. doi: 10.1002/hpm.930.
引用本文的文献
1
Progress, impacts and lessons from market shaping in the past decade: a systematic review.过去十年市场塑造的进展、影响及经验教训：一项系统综述
Front Public Health. 2025 Aug 21;13:1614471. doi: 10.3389/fpubh.2025.1614471. eCollection 2025.
2
A roadmap for affordable genetic medicines.负担得起的基因药物路线图。
Nature. 2024 Oct;634(8033):307-314. doi: 10.1038/s41586-024-07800-7. Epub 2024 Jul 17.
3
Association between expedited review designations and the US or global burden of disease for drugs approved by the US Food and Drug Administration, 2010-2019: a cross-sectional analysis.2010 - 2019年美国食品药品监督管理局批准药物的快速审查指定与美国或全球疾病负担之间的关联：一项横断面分析。
BMJ Open. 2024 Mar 12;14(3):e076542. doi: 10.1136/bmjopen-2023-076542.
4
Drugs for neglected tropical diseases: availability of age-appropriate oral formulations for young children.被忽视热带病药物：适合幼儿的适龄口服剂型的供应情况。
Parasit Vectors. 2022 Dec 12;15(1):462. doi: 10.1186/s13071-022-05546-7.
5
Antiparasitic Drugs in the United States-Two Roads to High Prices.美国的抗寄生虫药物——通往高价的两条途径。
Front Sociol. 2020 Oct 22;5:540478. doi: 10.3389/fsoc.2020.540478. eCollection 2020.
6
Optimization of 1,4-Naphthoquinone Hit Compound: A Computational, Phenotypic, and In Vivo Screening against .1,4-萘醌命中化合物的优化：针对. 的计算、表型和体内筛选
Molecules. 2021 Jan 15;26(2):423. doi: 10.3390/molecules26020423.
7
Priority Review Vouchers: GAO Report Provides Scant Evidence of Success.优先审评券：政府问责局的报告几乎没有提供成功的证据。
Clin Transl Sci. 2021 Jan;14(1):8-10. doi: 10.1111/cts.12878. Epub 2020 Sep 19.
8
Oral treatment with T6-loaded yeast cell wall particles reduces the parasitemia in murine visceral leishmaniasis model.口服负载 T6 的酵母细胞壁颗粒治疗可降低小鼠内脏利什曼病模型中的寄生虫血症。
Sci Rep. 2019 Dec 27;9(1):20080. doi: 10.1038/s41598-019-56647-w.
9
Is the priority review voucher program stimulating new drug development for tropical diseases?优先审评券计划是否刺激了热带病新药的开发？
PLoS Negl Trop Dis. 2018 Aug 9;12(8):e0006695. doi: 10.1371/journal.pntd.0006695. eCollection 2018 Aug.
10
Innovation in neglected tropical disease drug discovery and development.被忽视热带病药物研发的创新。
Infect Dis Poverty. 2018 Jun 18;7(1):67. doi: 10.1186/s40249-018-0444-1.
本文引用的文献
1
The Commercial Market For Priority Review Vouchers.优先审评券的商业市场。
Health Aff (Millwood). 2016 May 1;35(5):776-83. doi: 10.1377/hlthaff.2015.1314.
2
Experience With the Priority Review Voucher Program for Drug Development.药物开发优先审评券计划的经验
JAMA. 2015 Oct 27;314(16):1687-8. doi: 10.1001/jama.2015.11845.
Zotero 插件